

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/752,514	01/03/2001	Gary Klinefelter	KLINEFELTE	9981
1444	7590 03/19/2002		N. A.	-3
BROWDY AND NEIMARK, P.L.L.C.			EXAMINER	
624 NINTH S SUITE 300	,		NOLAN, P.	ATRICK J
WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
			1644	7
			DATE MAILED: 03/19/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 09/752,514

Applicant(s)

Examiner

Art Unit

Klinefelter

Office Action Summary

Patrick J. Nolan 1644

The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
Period for Reply	TO EXPIDE 1 MONTHS FROM
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.	
 Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communic If the period for reply specified above is less than thirty (30) days be considered timely. 	ation.
 If NO period for reply is specified above, the maximum statutory communication. 	period will apply and will expire SIX (6) MONTHS from the mailing date of this
- Failure to reply within the set or extended period for reply will, by	statute, cause the application to become ABANDONED (35 U.S.C. § 133). mailing date of this communication, even if timely filed, may reduce any
Status	
1) Responsive to communication(s) filed on	
2a) ☐ This action is FINAL . 2b) 💢 This act	tion is non-final.
3) Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 💢 Claim(s) <u>1-12</u>	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideratio
5) Claim(s)	is/are allowed.
6) Claim(s)	is/are rejected.
7) Claim(s)	is/are objected to.
8) 💢 Claims <u>1-12</u>	are subject to restriction and/or election requirement
Application Papers	
9) \square The specification is objected to by the Examiner.	
10)☐ The drawing(s) filed onis/ai	re objected to by the Examiner.
11) The proposed drawing correction filed on	is: all approved bl disapproved.
12) \square The oath or declaration is objected to by the Exam	iner.
Priority under 35 U.S.C. § 119	
13) \square Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).
a) \square All b) \square Some* c) \square None of:	
1. Certified copies of the priority documents have	ve been received.
2. Certified copies of the priority documents have	ve been received in Application No
 Copies of the certified copies of the priority depolication from the International Bure *See the attached detailed Office action for a list of the 	
14) Acknowledgement is made of a claim for domestic	
Attachment(s)	
5) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
(6) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
7) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:

Serial Number: 09/752,514

Art Unit: 1644

Part III DETAILED ACTION

1. Claims 1-12 are pending.

Restriction/Election

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
- Group I. Claims 1-2, drawn to antibodies to SP-22, classified in class 530, subclass 388.85.
- Group II. Claims 3-6, drawn to an assay for SP-22 levels, classified in class 435, subclass 4.
- Group III. Claims 7-8, drawn to a method of treating with antibodies, classified in class 424, subclass 152.1.
- Group IV. Claims 9 and 12 drawn to SP-22 or functional fragments thereof.
- Group V. Claims 10-11, drawn to method of treating with SP-22 or fragments thereof.

The inventions are distinct, each from the other because of the following reasons:

3. Groups I and IV are unique products. They differ with respect to their physicochemical properties and are therefore patentably distinct.

Groups II-III and V are unique methods. They differ with respect to ingredients and method steps. A assay and methods of treating with different agents represent patentably distinct subject matter.

Groups I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. 806.05(h)). In the present case, the product as claimed, the antibodies can be used in the assay of Group II.

Groups IV and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Serial Number: 09/752,514

Art Unit: 1644

process of using that product (M.P.E.P. 806.05(h)). In the present case, the product as claimed, the SP-22 protein or fragments thereof can be used in the assay of Group II.

- 4. Because a search of any of these five distinct inventions would not be co-extensive with a search of the others, an examination and search of two or more inventions in a single application would constitute a serious undue burden on the examiner.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor or at least one claim remaining in the application. Any amendment of the inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48 (b) and by the fee required under 37 CFR 1.17 (h).
- 7. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Tuesday through Friday from 9:00 am to 5:30 pm.
- 9. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7401. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Pátrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

March 19, 2002